confid deliv excel perform
maintain buy rate tp
provid upsid potenti
estim ep adjust ep
forward price-to-earnings multipl expect
revenu growth
estim base follow factor strong growth
revenu earn robust product line launch new
product strong growth laboratori product servic
segment innov technolog front
deliv strong revenu earn growth
total revenu increas
compar organ revenu growth
acquisit increas revenu currenc
translat increas revenu geograph
deliv double-digit growth china india south korea
end market perform pharma biotech
growth academ govern mid-
single-digit growth quarter diagnost healthcar
market low-single-digit growth quarter industri
appli market high-single-digit growth quarter
innov front lead technolog platform
includ new instrument softwar help custom
simplifi workflow better manag inform lab
also continu demonstr control custom
valu proposit especi pharma biotech
make great progress integr capabl gain
patheon acquisit
compani namethermo fisher scientif inctickertmostock ratingbuyunchangedindustri viewoverweightpositivepric may week week volum volum ep margin margin ttm per share growth profit ttm ttm incom ttm earn growth thermo fisher scientific| may
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
segment perform incom thermo fisher
report segment increas
total revenu laboratori product servic
segment increas
revenu analyt instrument segment
increas revenu
special diagnost segment increas
revenu life scienc solut
segment increas
oper incom increas
compar oper margin
compar
net incom increas
compar ep
compar non-gaap ep
increas compar previou
year quarter
thermo fisher launch new product across portfolio
includ thermo scientif vanquish duo uhplc system
pharma qa/qc thermo scientif chromeleon xtr
laboratori manag ion genestudio
seri next-gener sequenc instrument
guidanc expect revenu
growth
adjust ep estim
repres growth
adjust tax rate expect
tmo price-to-earnings multipl average stdev
deliv strong quarter result stock
volatil past three year current price-to-earnings
average stdev expect price-to-earnings
given buy rate stock tp
estim ep
stock price histori chang date high obsolet date obsolet move move share statist averag volum averag volum share held held share short short share short prior dividend split forward annual dividend forward annual dividend trail annual dividend trail annual dividend year averag dividend pay-out dividend date apr ex-dividend date last split factor new per last split date jun inform thermo fisher scientific| may
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
non- reconcili refer pg
incom statement item total gross research develop sell gener administr sg oper depreciation- oper profit interest incom special interest incom minor interest- incom incom net incom outstand dilut ep dilut ep actual annual estim annual actual quarterli thermo fisher scientific| may
 market account receivable- total prepaid expenses- current total current build machineri furnitur total fix non-curr defer incom taxes- non-curr total non-curr total equiti liabilitiesaccount accru defer current liabilities- total current long-term defer incom non-curr minor interest total non-curr total prefer stock equity- common stock addit paid-in retain treasuri total total total liabil stock actual annual actual quarterli balanc sheet item thermo fisher scientific| may
provid oper activ compar increas
account receiv inventori use cash support growth sale local
currenc thermo fisher made cash contribut pension postretir benefit
plan payment restructur action expens real estat consolid use
cash
tmo invest activ use cash acquisit use cash
thermo fisher financ activ use cash repay senior note use
cash net increas commerci paper oblig provid cash
depreciation- defer incom oper gains- increas decreas increas decreas current assets- decreas increas decreas increas current liabilities- decreas increas work non- net continu net discontinu operations- net total oper invest activitiessal properti plant purchas properti plant net invest financ activitiesissu issuanc capit repurchas capit payment financ charg discontinu financ activities- net financ net floweffect exchang rate net chang begin end thermo fisher scientific| may
start year strong note excel revenu earn
growth geograph deliv strong quarter result emerg
high growth region double-digit growth china india south korea
adjust ep increas first quarter
thermo fisher total revenu increas
compar revenu increas due
acquisit due favor effect currenc translat
due increas demand compar revenu
growth strong europ asia moder growth north america
cog increas compar
cog total revenu compar
total revenu
sg expens increas compar
sg expens total revenu compar
total revenu
 expens increas compar
 expens total revenu compar
total revenu
amort acquisition-rel intang asset
compar restructur cost
compar
oper incom increas compar
oper margin compar
increas oper incom due profit higher sale
local currenc also due effect acquisit product
improv increas inflationari cost off-set increas
amort acquisition-rel intang asset due recent acquisit
strateg growth invest
net incom increas compar
ep compar non-
gaap ep increas compar previou year
revenu increas
compar
increas
compar
margin
compar
pharma biotech
growth
continu
strength across
busi serv end
pharma biotech growth continu
strength across busi serv end market
academ govern grew mid-single-digit
diagnost health care low-single-digit growth
industri appli deliv high-single-digit growth
due continu strength end market
incom thermo fisher report segment increas
due profit higher sale local currenc also due
effect acquisit favor foreign currenc exchang product
improv increas inflationari cost off-set part strateg growth
total revenu segment increas
compar
revenu increas due higher revenu exist busi
due favor effect currenc translat increas
revenu exist busi due increas demand bioscienc
product bioprocess product product
oper margin compar
increas due product improv increas inflationari cost
profit higher sale local currenc favor foreign currenc
total revenu life
segment increas
compar
total revenu segment increas
compar
total revenu
segment increas
compar
revenu increas due higher revenu exist busi
due favor effect currenc translat due
acquisit increas revenu exist busi due
increas demand segment princip busi particularli
product sold segment electron microscopi busi
chromatographi mass spectrometri busi
oper margin compar
increas due profit higher sale local currenc product
improv increas inflationari cost off-set strateg growth
invest unfavor foreign currenc exchang
total revenu segment increas
compar
revenu increas due higher revenu exist busi
due favor effect currenc translat due
acquisit increas revenu exist busi due
higher demand particular strength sale product sold
segment healthcar market channel also due clinic diagnost
oper margin compar
decreas due unfavor sale mix strateg growth invest
off-set profit higher sale local currenc favor foreign
total revenu
segment increas
compar
laboratori product servic segment lp
total revenu segment increas
compar
total revenu lp
segment increas
compar
revenu increas due acquisit due higher
revenu exist busi due favor effect
currenc translat increas revenu exist busi due
increas demand product sold segment channel busi
clinic trial busi
oper margin compar
decreas due unfavor sale mix strateg invest off-set
profit higher sale local currenc
rais guidanc reflect strong oper
perform signific impact acquisit favor
expect revenu
growth
adjust ep estim repres
growth
deliv strong perform robust growth revenu
earn tmo revenu increas compar
previou year quarter adjust ep grew
compar previou year quarter
laboratori product servic segment revenu increas
launch new product across portfolio includ
thermo scientif vanquish duo uhplc system pharma qa/qc thermo
scientif chromeleon xtr laboratori manag ion
genestudio seri next-gener sequenc instrument
oper margin increas compar
adjust oper margin compar
ytd stock perform roe ttm
expect revenu
growth
launch new
product across
system ion
genestudio seri
non- reconcili
non- reconcili
non- reconcili
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
gross margin ttm compar
revenu growth ttm compar
ep growth ttm compar
ratio revenu margin margin inc margin rate margin turnov averag asset leverag averag equiti year averag averag averag year averag averag averag year averag averag averag growth growth ex sale /sale /net incom ratio profit marginsprofitabilityrevenu growth oper incom growthep growth thermo fisher scientific| may
mrqgross mrqcog mrqsg mrqoper mrqnet mrqr sale thermo fisher scientific| may
inv flow sale
mrqyoy growth revenu growthoper incom growthep mrqfinanci mrqreturn mrqreturn mrqcapex salescap ex salesfre mrq ratio growth yoy oper growth yoy free growth yoy thermo fisher scientific| may
per share item ratio
fiscal per ebitda per ebit per earn per share ep ep free flow per dividend per book valu per tangibl book per month end stock month end stock equiti return asset return invest capit return capit joel greenblatt debt gross margin oper margin net margin total equiti total lt debt total asset dividend pay-out day sale day account day convers inventori cog inventori tax rate net incom net incom net net margin prefer dividends- annual itemsquarterli item thermo fisher scientific| may
balanc sheet item
outstand equival market debt common prefer stock- purchas properti plant sale properti plant purchas sale purchas investment- sale issuanc repurchas stock- net issuanc prefer stock- net issuanc net chang capit free thermo fisher scientific| may
price-to-earnings averag price-to-earnings current price-to-earnings
average stdev expect price-to-earnings
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
breakdown share held share held float held institut hold direct holder form marc peter scott andrew alan thoma jim patrick institut holdersholdershar report outvaluevanguard group inc massachusett servic capit research global capit world price row associ wellington manag compani america fmr top mutual fund holdersholdersharesd report outvaluevanguard total stock market growth fund america vanguard amcap spdr etf vanguard institut fund-institut vanguard specialized-health fundament investor mf seri trust i-mf valu ishar thermo fisher scientific| may
developmentsthermo fisher scientif instal first glacio cryo-electron microscop drug discoveri developmentthermo fisher scientif world leader serv scienc announc leader innov drug discoveri develop select thethermo scientif glacio cryo transmiss electron microscop cryo-tem aid drug discoveri develop program astex research focus oncolog diseas central nervou system tmowil instal glacio cryo-tem research develop headquart incambridg uk thermo fisher scientif unveil gibco expisf system first chemic defin insect protein express systemthermo fisher scientif announc itsgibco expisfsystem first-ev chemic defin insect protein express system revolutionari expisf system bring togeth compani gibco media technolog lipofectamin transfect technolog molecular biolog expertis deliv three time protein consist result thermo fisher leica collabor develop integr cryo-tomographi workflow solutionthermo fisher scientif leica microsystem announc technolog collabor develop integr comprehensivecryo-tomographyworkflow life scienc hardwar softwar solut intend seamlessli integr light microscop leica cryo-electron microscop fromthermo fisherprovid research scientist faster better insight mechan diseas acceler scientif discoveri thermo fisher scientif acquir integenx provid lead rapid dna technolog human identificationthermo fisher scientif inc world leader serv scienc announc acquiredintegenxinc provid rapid dna platform use forens law enforc applic integenx product significantli enhancethermo fisher sexist hid portfolio complement lead human identif chemistri well qpcr capillari electrophoresi system may thermo fisher scientific| may
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
compar
gross margin ttm
compar
industri averag
sale growth ttm
compar
industri averag
actual vs price-to-earnings ratio ttm price-to-earnings high last yr price-to-earnings last yr beta price sale ttm price book mrq price ttm price free ttm errorerrorerror own dividend yield dividend yield year average dividend year growth rate pay-out ratio ttm sale mrq vs qtr yr sale ttm vs ttm yr sale yr growth rate sale yr growth rate ep mrq vs qtr yr ep ttm vs ttm yr ep yr growth rate ep yr growth rate capit spend yr growth rate lt debt equiti mrq total debt equiti mrq interest coverag ttm gross margin ttm gross margin yr average ebitd margin ttm ebitd yr average oper margin ttm oper margin yr average pre-tax margin ttm pre-tax margin yr average net profit margin ttm net profit margin yr average effect tax rate ttm effect tax rate yr average return asset ttm return asset yr average return invest ttm return invest yr average return equiti ttm return equiti yr average revenue/employe ttm net income/employe ttm receiv turnov ttm inventori turnov ttm asset turnov ttm manag effect effici performancevalu ratio dividend growth rate ratio profit thermo fisher scientific| may
consensu view analyst trend stock
lower
growth rate
forward price-to-earnings
higher
valuat comparisontmoindustri avg avgprice/earn yield usdgrowth high day day day estim avgfive-year growth forecast thermo fisher scientific| may
consensu view analyst trend stock
averag earn estim
current qtr
next qtr
sale growth estim current
qtr
averag revenu estim
estimatescurr analyst estimatethi estim estimatepast ep growthprice/earningsobsoleteobsoleteobsoleteobsoletepeg ratioobsoleteobsoleteobsoleteobsoleteconsensu ep day day day day ep revisionsn/an/an/an/aup last last daysn/an/an/an/adown last dayserrorerrorerrorerrordown last dayscurr surprisescurr growth rate analyst recommend
incom statement
guidanc
non-
per share item
balanc sheet
product perform develop
valuat consensu perform
stock volatil throughout quarter trade around may
stock given total return last month
stock price show increas trend last one year reach may
stock shown consist rise price last year given total return
reach fresh high
stock shown signific rise price sinc may reach time high
stock given total return last year
thermo fisher scientif deliv strong revenu earn growth launch
new product across portfolioa well maintain buy rate stock tp
crispidea financi inform servic firm focus provid equiti research portfolio manag
person wealth manag brokerag servic inform servic side provid commun
consult research servic host client
crispidea track limit number compani sector strive provid qualiti insight straight
forward analysi object creat long-term wealth moder low risk crispidea leverag
larg number in-hous extern expert oper within industri strong financi oper
strateg background
detail visit www crispidea com contact
